Gilead announces licence and collaboration deal with Yuhan
10-01-2019
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25-07-2018
Avosb / iStockphoto.com
Germany’s Federal Patent Court (Bundespatentgericht, BpatG) has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate (SPC) for HIV/AIDS treatment Truvada,
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead Sciences, Truvada, Bundespatentgericht, patent infringement, HIV/AIDS treatment, supplementary protection certificate, basic patent, EU patent law
